Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.04 USD
Change Today +0.47 / 6.21%
Volume 86.7K
ARGS On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

argos therapeutics inc (ARGS) Snapshot

Open
$7.86
Previous Close
$7.57
Day High
$8.21
Day Low
$7.78
52 Week High
09/10/14 - $10.80
52 Week Low
07/29/14 - $5.61
Market Cap
158.3M
Average Volume 10 Days
35.1K
EPS TTM
$-3.26
Shares Outstanding
19.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ARGOS THERAPEUTICS INC (ARGS)

Related News

No related news articles were found.

argos therapeutics inc (ARGS) Related Businessweek News

No Related Businessweek News Found

argos therapeutics inc (ARGS) Details

Argos Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on Arcelis, its proprietary technology platform. Its development stage products include AGS-003, which is under Phase III clinical trials for the treatment of metastatic renal cell carcinoma and other cancers; and AGS-004, which is in phase 2 clinical trial for the treatment of Human Immunodeficiency Virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is headquartered in Durham, North Carolina.

113 Employees
Last Reported Date: 03/31/15
Founded in 1997

argos therapeutics inc (ARGS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $543.6K
Chief Operating officer and Vice President of...
Total Annual Compensation: $357.0K
Chief Scientific Officer and Vice President o...
Total Annual Compensation: $382.5K
Compensation as of Fiscal Year 2014.

argos therapeutics inc (ARGS) Key Developments

Argos Therapeutics, Inc. Enters into License Agreement with Lummy (Hong Kong) Co. Ltd

On April 7, 2015, Argos Therapeutics, Inc. and Lummy (Hong Kong) Co. Ltd., entered into a license agreement whereby the company granted to Lummy HK an exclusive license under the Arcelis technology, including patents, know-how and improvements to manufacture, develop and commercialize products for the treatment of cancer in China, Hong Kong, Taiwan and Macau. Lummy HK also has a right of first negotiation with respect to a license under the Arcelis technology for the treatment of infectious diseases in the Territory. Under the terms of the License Agreement, the parties will share relevant data, and the Company will have a right to reference Lummy HK data for purposes of its development programs under the Arcelis technology. In addition, Lummy HK has granted to the company an exclusive, royalty-free license under and to any and all Lummy HK improvements to the Arcelis technology conceived or reduced to practice by Lummy HK and Lummy HK data to develop and/or commercialize products outside the Territory; an exclusive, royalty-free license under and to any and all INDs and other regulatory approvals and Lummy HK trademarks used for an Arcelis-Based Product to develop and/or commercialize an Arcelis-Based Product outside the Territory; and a non-exclusive, worldwide, royalty-free license under any Lummy HK Improvements and Lummy HK data to manufacture Arcelis-Based Products anywhere in the world. Lummy HK has the right to reference Company's data, INDs and other regulatory filings and submissions for the purpose of developing and obtaining regulatory approval of Licensed Products in the Territory. Pursuant to the License Agreement, Lummy HK will pay the Company royalties on net sales and up to an aggregate of $20 million upon the achievement of manufacturing, regulatory and commercial milestones. The License Agreement will terminate upon expiration of the last to expire royalty term for all Arcelis-Based Products, with each royalty term being the longer of the expiration of the last valid patent claim covering the applicable Arcelis-Based Product and 10 years from the first commercial sale of such Arcelis-Based Product.

Argos Therapeutics, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Argos Therapeutics, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenue was $303,453, compared to revenue of $715,747 in the fourth quarter of 2013. Net loss attributable to common stockholders was $16,220,410, or $0.83 per share compared to a net loss of $8,497,951, or $36.19 per share for the fourth quarter ended December 31, 2013. Operating loss was $15,635,750 against $7,973,472 a year ago. Net loss was $16,220,410 against $8,020,922 a year ago. For the year, revenue was $1,974,019, compared to revenue of $4,421,689 for the year ended December 31, 2013. Net loss attributable to common stockholders was $54,169,164, or $3.12 per share compared to a net loss of $33,874,660, or $147.37 per share for the year ended December 31, 2013. Operating loss was $52,124,256 against $24,231,779 a year ago. Net loss was $53,305,938 against $23,921,563 a year ago.

Argos Therapeutics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 02:20 PM

Argos Therapeutics, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 02:20 PM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Jeffrey D. Abbey, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARGS:US $8.04 USD +0.47

ARGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $18.09 USD +1.02
Eurocine Vaccines AB kr2.77 SEK +0.02
Genocea Biosciences Inc $10.29 USD +0.17
GenVec Inc $2.37 USD -0.05
Inovio Pharmaceuticals Inc $8.46 USD +0.04
View Industry Companies
 

Industry Analysis

ARGS

Industry Average

Valuation ARGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 75.4x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARGOS THERAPEUTICS INC, please visit www.argostherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.